^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABBV-706
i
Other names: ABBV-706, ABBV706, ABBV 706
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie
Drug class:
Topoisomerase I inhibitor, SEZ6-targeted antibody-drug conjugate
Related drugs:
10d
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. (PubMed, Nat Med)
Based on the totality of available data, including, but not limited to, safety, preliminary efficacy measures and PK, 1.8 mg kg-1 Q3W was confirmed as the optimal RP2D for patients with R/R SCLC. ClinicalTrials.gov: NCT05599984 .
P1 data • Journal
|
SEZ6 (Seizure Related 6 Homolog)
|
ABBV-706
1m
M23-385: Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=288, Active, not recruiting, AbbVie | Trial completion date: Jun 2026 --> Nov 2027 | Trial primary completion date: Jun 2026 --> Nov 2027
Trial completion date • Trial primary completion date • Adverse events • First-in-human
|
EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
|
EGFR mutation • IDH wild-type
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
2ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | N=60 --> 180
Enrollment change • Trial initiation date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
3ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | N=50 --> 180
Enrollment change • Trial initiation date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
3ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=50, Recruiting, AbbVie | N=27 --> 50
Enrollment change • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
3ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | N=27 --> 180
Enrollment change • Trial initiation date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
3ms
New P2 trial • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
3ms
M24-633: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Participants with Previously Untreated Extensive Stage Small Cell Lung Cancer (2024-517490-24-00)
P1/2, N=18, Not yet recruiting, AbbVie Deutschland GmbH & Co. KG
New P1/2 trial • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • ABBV-706
5ms
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=531, Not yet recruiting, AbbVie
New P3 trial • Adverse events
|
topotecan • Zepzelca (lurbinectedin) • ABBV-706 • Calsed (amrubicin)
5ms
Expanded Access to ABBV-706 (clinicaltrials.gov)
P=N/A, N=0, Available, AbbVie
New trial
|
ABBV-706
6ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | Trial completion date: May 2029 --> Sep 2031
Trial completion date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
6ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | Trial completion date: Sep 2031 --> May 2029
Trial completion date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
Share via
